Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

To evaluate the efficacy and safety of using nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) in the primary treatment of locoregionally advanced nasopharyngeal carcinoma. Between December 2009 and December 2013, 38 newly diagnosed patients with stage III-IV nasopharyngeal car...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2015-01, Vol.8, p.3383-3390
Main Authors: Zhai, Rui-Ping, Ying, Hong-Mei, Kong, Fang-Fang, Du, Cheng-Run, Huang, Shuang, Zhou, Jun-Jun, Hu, Chao-Su
Format: Article
Language:English
Subjects:
Brain research
Cancer therapies
Care and treatment
Chemotherapy
Lymphatic system
Medical imaging
Medical prognosis
Methods
Monoclonal antibodies
Nasopharyngeal cancer
Nimotuzumab
NMR
Nuclear magnetic resonance
Oncology
Original Research
Patient outcomes
Radiation therapy
Radiotherapy
Spinal cord
Targeted cancer therapy
Throat cancer
Tomography
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and safety of using nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) in the primary treatment of locoregionally advanced nasopharyngeal carcinoma. Between December 2009 and December 2013, 38 newly diagnosed patients with stage III-IV nasopharyngeal carcinoma were treated with IMRT and nimotuzumab concomitantly. The distribution of disease was stage III in 20 (52.6%), stage IV A in 9 (23.7%), and stage IV B in 9 (23.7%). All the patients received at least two cycles of cisplatin-based neoadjuvant chemotherapy followed by nimotuzumab 200 mg/week concurrently with IMRT. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of Radiation Therapy Oncology Group. With a median follow-up of 39.7 months (range, 13.3-66.5 months), the estimated 3-year local recurrence-free survival, regional recurrence-free survival, distant metastasis-free survival, progression failure-free survival, and overall survival rates were 92.8%, 92.9%, 89.5%, 78.7%, and 87.5%, respectively. The median cycle for nimotuzumab addition was 6 weeks. Grade 3 radiation-induced mucositis accounted for 36.8% of treated people. No skin rash and infusion reaction were observed, distinctly from what is reported in cetuximab-treated patients. Nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities for patients.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S93238